Not exact matches
In order to
find out how and why
ovarian cancer cells grow and take on such lethal characteristics, Dr. Shepherd and his team grow the
cancer cells in 3D structures, called «spheroids» — the same way the
cancer cells grow in
patients.
«Our
findings suggest that this new drug combination would also help
patients with this type of aggressive breast
cancer as well as other
cancers, such as lung, prostate and
ovarian cancers,» Dr. Rassool says.
Analyzing white blood cells from 934
patients and 1,698 healthy controls, they
found BRCA1 methylation among 6.4 % of
patients diagnosed with
ovarian cancer, contrasting 4.2 % among controls.
This test may be particularly useful for
patients with high grade serous
ovarian cancer because the mutated
cancer gene TP53 is
found in more than 99 per cent of
patients with this form of the disease.
«In
patients with
ovarian cancer, we
found more pathogenic types of bacteria.»
The research team with international collaborators analysed more than 100
patient samples from
ovarian and other
cancer types to discover a distinct population of cells
found in some tumours.
When post-surgery DNA matched that of the tumor,
patients were later
found to have had a recurrence of
ovarian cancer.
«If studies in larger groups of women confirm our
finding that the fallopian tubes are the site of origin of most
ovarian cancer, then this could result in a major change in the way we manage this disease for
patients at risk.»
In their research, scientists at Rutgers created animal models that closely resemble the cancerous tumors
found in women with
ovarian cancer by injecting tumor tissues obtained from gynecological cancer patients treated at the Cancer Institute into laboratory
cancer by injecting tumor tissues obtained from gynecological
cancer patients treated at the Cancer Institute into laboratory
cancer patients treated at the
Cancer Institute into laboratory
Cancer Institute into laboratory mice.
Notably, the researchers
found that, using their methods, highly reactive TILs could be obtained from some 90 % of the
ovarian cancer patients whose tumor samples they examined.
«I want to
find those early - stage tumors, and I want to increase the survival of
patients with
ovarian cancer.»
Go to our
Cancer Immunotherapy Clinical Trial Finder to find clinical trials of immunotherapies for ovarian cancer that are currently enrolling pat
Cancer Immunotherapy Clinical Trial Finder to
find clinical trials of immunotherapies for
ovarian cancer that are currently enrolling pat
cancer that are currently enrolling
patients.
Together, these and other
findings strongly suggest that immunotherapies that can induce or enhance optimal immunologic conditions within
ovarian cancers may hold great promise for extending the lives of
ovarian cancer patients.
Cancer patients who have
ovarian tissue removed and stored for later transplantation have a chance at a successful pregnancy, a new study
finds.
A study presented at the SGO Annual Meeting
found that PARP - 7 amplification mutations are associated with prolonged survival among
patients with platinum - sensitive
ovarian cancer.
«We are committed to turning discoveries such as this, as well as our recent
findings in
ovarian cancer and sick sinus syndrome, and our future discoveries, into real benefit for
patients,» Dr. Stefansson continued.
They even
found talcum powder particles in the tumors of the
ovarian cancer patients they studied.